Company / Shareholders' Equity
Relay Therapeutics, Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$567.1M
FY2025
5-year range
-$180.4M / $777.8M
FY2021-FY2025
Trend
-27.1%
vs FY2024
Sector context
#87 of 213
Health Care
What the data says
At $567M, Relay Therapeutics, Inc.'s shareholders' equity ranks #87 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 7 years, ranging from -$180M in FY2021 to $778M in FY2024.
Based on SEC 10-K filings.
$567M in FY2025 with a 3-year CAGR of -9.4%.
Declined from $752M to $567M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -9.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#87 of 213 in Health CareTop 41% of 213This company $567.1M Sector average $2.5B
▼
-77.7% below sector average
Key checks
Key Insights
- 3-year CAGR of -9.4%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 27.1% year-over-year.
- Ranks #87 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $567.1M | -27.1% |
| FY2024 | $777.8M | +3.4% |
| FY2023 | $752.0M | -1.5% |
| FY2022 | $763.3M | +523.0% |
| FY2021 | -$180.4M | -62.7% |
| FY2020 | -$110.9M | +38.5% |
| FY2019 | -$180.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026